Diaceutics
Diaceutics is a data analytics and services company providing pharmaceutical and biotechnology clients with an end-to-end solution for the commercialisation of precision medicine diagnostics.
The company integrates real-world diagnostic testing data from a global network of over 52,000 laboratories, applying machine learning to map patient diagnostic pathways across 53 countries.
Services include biomarker adoption analytics, physician engagement, lab network management, and field-based diagnostic implementation.
Latest News
Diaceutics and PCC Launch NGS Concordance Study
Diaceutics has partnered with the Precision Cancer Consortium to launch an NGS Concordance Study evaluating variant detection consistency across up to 20 next-generation sequencing panels and platforms used in US clinical laboratories. The study benchmarks detected genomic variants against reference profiles in synthetic samples, aiming to improve transparency and confidence in biomarker testing for precision oncology.
Diaceutics Reports 22% H1 Revenue Growth, 75% ARR Surge
Diaceutics reported H1 2026 revenue up 22% to £17.5m, with annual recurring revenue up 75%, driven by higher net revenue retention and an expanding pharma and biotech customer base across 99 therapeutic brands. A £43.7m order book, including £15.7m already contracted for H2, gives the company 91% visibility on meeting full-year 2026 revenue targets.